End-of-day quote
Shanghai S.E.
06:00:00 2024-05-19 pm EDT
|
5-day change
|
1st Jan Change
|
5.19
CNY
|
+0.78%
|
|
-1.89%
|
-15.33%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,951
|
2,505
|
2,735
|
5,056
|
3,544
|
3,429
|
Enterprise Value (EV)
1 |
2,359
|
3,066
|
3,365
|
5,615
|
3,824
|
3,859
|
P/E ratio
|
-16.9
x
|
55.6
x
|
93.6
x
|
839
x
|
-49.6
x
|
79.2
x
|
Yield
|
-
|
-
|
0.32%
|
0.11%
|
-
|
-
|
Capitalization / Revenue
|
1.63
x
|
1.91
x
|
1.93
x
|
3.15
x
|
1.81
x
|
1.66
x
|
EV / Revenue
|
1.97
x
|
2.34
x
|
2.37
x
|
3.5
x
|
1.95
x
|
1.86
x
|
EV / EBITDA
|
20.7
x
|
21
x
|
28.7
x
|
34.2
x
|
97.1
x
|
30.4
x
|
EV / FCF
|
-169
x
|
-31.2
x
|
-95.2
x
|
45.2
x
|
10.6
x
|
-39
x
|
FCF Yield
|
-0.59%
|
-3.21%
|
-1.05%
|
2.21%
|
9.45%
|
-2.57%
|
Price to Book
|
1.41
x
|
1.91
x
|
1.88
x
|
3.04
x
|
2.3
x
|
2.17
x
|
Nbr of stocks (in thousands)
|
573,886
|
548,076
|
545,985
|
563,040
|
556,382
|
559,363
|
Reference price
2 |
3.400
|
4.570
|
5.010
|
8.980
|
6.370
|
6.130
|
Announcement Date
|
3/29/19
|
3/27/20
|
4/28/21
|
4/19/22
|
4/6/23
|
3/27/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,195
|
1,312
|
1,417
|
1,605
|
1,961
|
2,070
|
EBITDA
1 |
113.7
|
145.8
|
117.3
|
163.9
|
39.37
|
126.8
|
EBIT
1 |
62.83
|
106.7
|
76.23
|
120.3
|
-7.866
|
75.94
|
Operating Margin
|
5.26%
|
8.14%
|
5.38%
|
7.5%
|
-0.4%
|
3.67%
|
Earnings before Tax (EBT)
1 |
-115.3
|
51.23
|
29.24
|
7.45
|
-82.85
|
42.96
|
Net income
1 |
-115.3
|
45.71
|
29.24
|
5.995
|
-72.14
|
43.56
|
Net margin
|
-9.65%
|
3.48%
|
2.06%
|
0.37%
|
-3.68%
|
2.1%
|
EPS
2 |
-0.2009
|
0.0822
|
0.0535
|
0.0107
|
-0.1283
|
0.0774
|
Free Cash Flow
1 |
-13.99
|
-98.32
|
-35.35
|
124.2
|
361.3
|
-99.01
|
FCF margin
|
-1.17%
|
-7.49%
|
-2.49%
|
7.74%
|
18.43%
|
-4.78%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
75.77%
|
917.55%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
2,071.8%
|
-
|
-
|
Dividend per Share
|
-
|
-
|
0.0160
|
0.0100
|
-
|
-
|
Announcement Date
|
3/29/19
|
3/27/20
|
4/28/21
|
4/19/22
|
4/6/23
|
3/27/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
408
|
562
|
630
|
559
|
280
|
430
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
3.586
x
|
3.851
x
|
5.366
x
|
3.407
x
|
7.101
x
|
3.391
x
|
Free Cash Flow
1 |
-14
|
-98.3
|
-35.3
|
124
|
361
|
-99
|
ROE (net income / shareholders' equity)
|
-7.96%
|
3.33%
|
1.87%
|
0.41%
|
-4.46%
|
2.77%
|
ROA (Net income/ Total Assets)
|
1.39%
|
2.39%
|
1.51%
|
2.1%
|
-0.13%
|
1.32%
|
Assets
1 |
-8,286
|
1,910
|
1,940
|
286
|
54,200
|
3,296
|
Book Value Per Share
2 |
2.420
|
2.400
|
2.660
|
2.950
|
2.770
|
2.820
|
Cash Flow per Share
2 |
1.170
|
0.7300
|
0.8900
|
0.6800
|
0.5500
|
0.3500
|
Capex
1 |
66.4
|
108
|
72.7
|
39.1
|
66.6
|
43.1
|
Capex / Sales
|
5.56%
|
8.21%
|
5.13%
|
2.44%
|
3.4%
|
2.08%
|
Announcement Date
|
3/29/19
|
3/27/20
|
4/28/21
|
4/19/22
|
4/6/23
|
3/27/24
|
|
1st Jan change
|
Capi.
|
---|
| -15.33% | 400M | | +34.35% | 705B | | +30.93% | 583B | | -3.49% | 364B | | +20.15% | 332B | | +6.19% | 291B | | +14.79% | 238B | | -3.68% | 210B | | +9.98% | 209B | | +9.21% | 169B |
Other Pharmaceuticals
|